Global Healthy Living Foundation
515 North Midland Avenue
Upper Nyack, New York 10960 USA
+1 845 348 0400
+1 845 348 0210 fax
www.ghlf.org

February 15, 2013

Senator Aaron Bean
302 Senate Office Building
404 South Monroe Street
Tallahassee, FL 32399-1100

RE: **SB 732 – *Support***

Dear Senator Bean:

I am writing you today on behalf of the Global Healthy Living Foundation (GHLF) and the more than 56,000 members we represent, including approximately 7800 in Florida, to express our support for SB 732. We represent patients living with chronic illnesses nationwide, from those with osteoporosis to those with chronic mental illness. Many of the patients we represent, including the nearly 30,000 with Rheumatoid Arthritis, take biologics.

At the GHLF, our focus is on improving the lives of patients with chronic illnesses through health care education and mobilization programs that stress the importance of diagnosis, early and innovative medical intervention, long-term lifestyle improvement and therapeutic compliance. Using various channels of influence, we work to communicate and leverage new and improved medical treatments, such as biologics, to patients. As promising as these innovative drugs are, GHLF believes that assuring their safety should be of paramount concern.

We believe that SB 732 takes positive steps toward updating Florida law to cover biologics and biosimilars in a way that protects patients. Unlike traditional chemical drugs, biologics have very unique, complex structures made from living cells that are not easily understood or replicated. A small change or difference in the biosimilar or biologic has the potential to either help or adversely affect the patient.

There are two provisions in SB 732 that the GHLF believes are key to ensuring patients' safety and needs are met in the best way possible. First, the bill requires a pharmacist dispensing an interchangeable biosimilar to notify the prescribing physician and the patient. Second, the pharmacist and prescribing health care provider must also keep a written record of the substitution for at least four years.

For patients, these two provisions are crucial. A determination of product interchangeability could take the decision-making process out of the hands of patients and doctors and put it into the hands of the pharmacists or insurers through states' automatic substitution policies. We

believe that the choice of product should be decided only by patients and physicians, who are ultimately responsible for patient care and have the full spectrum of a patient's medical history. In addition, if it is determined by the doctor and patient that an interchangeable biosimilar can be substituted for a biologic, or is the preferred treatment in a particular case, it is important that proper record keeping be in place in order to track any adverse events that may occur.

As patient advocates, it is our duty to ensure that patients and physicians are in charge of the drugs prescribed, that patient safety is the top priority in the health care process and that medical decisions remain between a doctor and his or her patient. We urge the passage of SB 732 because it introduces biosimilars in a way that ensures the safety of patients and preserves the physician-patient relationship.

We appreciate your thoughtful consideration of this legislation and would be pleased to provide any further information that you may require.

Sincerely,

Seth Ginsberg
President, Global Health Living Foundation

CC: Senator Denise Grimsley
Members, Senate Health Policy Committee